Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Rating of “Hold” from Brokerages

Moderna, Inc. (NASDAQ:MRNA) has earned an average rating of “Hold” from the sixteen research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $129.55.

A number of equities research analysts have weighed in on the stock. HSBC reiterated a “reduce” rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. William Blair reissued a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Royal Bank of Canada increased their price objective on shares of Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a research report on Friday. Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. Finally, Oppenheimer increased their price target on shares of Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a research note on Friday.

Insiders Place Their Bets

In other news, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $225,833.16. Following the transaction, the president now directly owns 1,515,898 shares of the company’s stock, valued at approximately $143,358,473.86. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, insider Shannon Thyme Klinger sold 670 shares of Moderna stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $63,361.90. Following the completion of the transaction, the insider now directly owns 8,557 shares of the company’s stock, valued at $809,235.49. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the sale, the president now directly owns 1,515,898 shares in the company, valued at approximately $143,358,473.86. The disclosure for this sale can be found here. Over the last quarter, insiders sold 139,954 shares of company stock worth $14,822,576. 15.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Moderna

Institutional investors and hedge funds have recently made changes to their positions in the business. Ogorek Anthony Joseph NY ADV purchased a new stake in shares of Moderna in the fourth quarter valued at about $27,000. Arlington Trust Co LLC lifted its stake in Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after buying an additional 290 shares in the last quarter. Westside Investment Management Inc. acquired a new stake in Moderna during the 1st quarter valued at $32,000. Rise Advisors LLC increased its position in Moderna by 953.3% during the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after buying an additional 286 shares in the last quarter. Finally, UMB Bank n.a. raised its holdings in shares of Moderna by 121.8% in the first quarter. UMB Bank n.a. now owns 366 shares of the company’s stock worth $39,000 after acquiring an additional 201 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Stock Down 2.3 %

Shares of NASDAQ MRNA opened at $122.13 on Thursday. The company has a market capitalization of $46.81 billion, a P/E ratio of -7.79 and a beta of 1.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The company has a 50 day simple moving average of $105.61 and a 200-day simple moving average of $94.76. Moderna has a 1 year low of $62.55 and a 1 year high of $142.79.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. During the same quarter last year, the firm earned $0.19 earnings per share. The firm’s quarterly revenue was down 91.0% compared to the same quarter last year. On average, equities research analysts predict that Moderna will post -7.47 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.